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Iron containing monooxygenases play diverse roles in nature, ranging from the primary
metabolic functions of alkane hydroxylases to the xenobiotic detoxification and secondary
metabolic roles of cytochrome P450 enzymes..[1] Common to these enzymes is the ability to
reductively activate molecular oxygen to generate highly electrophilic oxygen species,
whose reactivity is comparable with that of ‘oxenes’ (oxygen atoms containing six-valence
electrons).[2] P450 enzymes in particular possess the remarkable ability to insert oxygen
atoms at virtually any position within otherwise unreactive carbon skeletons leading to the
synthesis of alcohols or epoxides in diverse natural products.
Whereas enzymes are capable of inserting oxygen atoms into even unactivated C-H bonds,
the sites into which nitrogen can be incorporated are more constrained. Transaminases,
ammonia lyases, and amino acid dehydrogenases, for example,[3] target oxidized or
otherwise chemically activated carbons for reaction. Enzymes that catalyze the concerted
oxidative amination of C-H bonds are apparently absent from nature's repertoire of chemical
catalysts.
Synthetic chemists, who are not limited to biologically accessible reagents and metals, have
developed highly useful methods for the oxidative formation of C-N bonds.[4] These C-H
amination reactions often proceed through a nitrenoid intermediate that has no parallel in
natural enzymes. Although these reactions do not require preoxidized or otherwise activated
carbon atoms, they do require specialized nitrene-precursors such as azides, haloamines, or
iminoiodinanes. Of the many transition-metal catalysts based on Rh, Ru, Mn, Co, and Fe
that catalyze intra- and intermolecular C-H amination, we were especially interested in the
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metal-porphyrin systems,[5] which react with iminoiodinanes in the +3 oxidation state to
catalyze nitrene transfers that are isoelectronic with the well-established formal oxene
transfer reaction of ferric-P450 enzymes with iodosylbenzene.[5a, 6] Trace levels (3 total
turnovers; TTNs) of intramolecular C-H amination were reported more than 25 years ago for
mammalian cytochrome P450 preparations reacting with iminoiodinanes.[7] We decided to
revisit the possibility of finding or engineering an enzyme catalyst for this useful and
challenging transformation.
Iminoiodinanes, however, are problematic for biocatalytic application, given their polymeric
nature[8] and insolubility[9] in aqueous media. As an alternative to iminoiodinanes, we
decided to focus on the synthetic reaction of sulfonylazides with reduced (+2 oxidation
state) metal porphyrins.[10] We reasoned that such a "chemomimetic" approach to achieving
direct C-H to C-N conversion could provide a biocatalytic route to amines and amides using
biochemically compatible and atom-efficient azide-based nitrene precursors, with the usual
enzyme advantages of selectivity and mild reaction conditions. Here we report the first
highly active enzyme catalysts of C-H amination.
In initial experiments, we tested a panel of 24 purified cytochrome P450BM3 variants
developed for monooxygenation reactions. Enzymes were reacted with 2,4,6-
triethylbenzene-1-sulfonylazide (1) under anaerobic, reducing conditions at an enzyme
loading of 0.5 mol% in aqueous media (phosphate buffer, 2.5% v/v DMSO). Most reactions
gave sulfonamide 2 as the major product, though all of the tested enzymes, including wild-
type (4 TTN), yielded small amounts of the C-H amination product, 3. The most active
enzyme for C-H amination in the initial screen contained only a single mutation (T268A)
relative to wild-type P450BM3 (28 TTN). Although mutations to the active site residue T268
are deleterious to monooxygenation activity given its role in promoting O-O bond scission,
the T268A mutation was recently shown to promote P450BM3-catalyzed carbene transfers
yielding cyclopropanes.[11] Thus, in spite of the significant differences between carbene and
nitrene chemistry, we proceeded to test several P450BM3-based cyclopropanation catalysts,
including several serine-heme ligated ‘P411’[12] enzymes (so called because the Soret peak
in the ferrous CO-bound spectrum is shifted to 411 nm rather than 450 nm for cysteine
ligated enzymes) in which the axial coordinating cysteine C400, absolutely required for
monooxygenation activity, is mutated to serine. Given that loss of dinitrogen from azides is
much more facile than O-O bond scission catalyzed by P450s, we reasoned that the ‘thiolate
push’ of the axial cysteine would be unnecessary for C-H amination.[13] The most active
enzyme here was the C400S mutant P411BM3-CIS (14 mutations from wild-type), which
also contained the T268A mutation and supported over 140 total turnovers (73% yield of 3
by HPLC). Variant P450BM3-CIS, which lacks the C400S mutation at the axial heme ligand,
was significantly less active (9 TTN), indicating that serine-heme ligation strongly enhances
BM3-catalyzed C-H amination. The P450BM3-C400S single mutant (P411BM3) also
exhibited markedly improved activity (49 TTN) relative to its cysteine-ligated counterpart,
P450BM3 (4 TTN).
To clarify the roles of the T268A and C400S mutations in BM3-catalyzed amination, we
performed further experiments at 0.1 mol% catalyst loading with the P450BM3-T268A and
P411BM3 (BM3-C400S) single mutants as well as the T268A/C400S double mutant in
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reaction with sulfonyl azide 1 (Table 1). We found that the T268A and C400S mutations
combined to yield a highly active enzyme (120 TTN for the double mutant versus 310 TTN
for P411BM3-CIS, Table 1), indicating that the T268A and C400S mutations were major
contributors to the high activity of P411BM3-CIS. In fact, reverting the T268A mutation in
P411BM3-CIS markedly reduced activity (82 TTN).
Control experiments revealed that the enzyme-catalyzed reaction was inhibited by carbon
monoxide, air, and heat denaturation of the enzyme, all of which suggests that catalysis
occurs at the enzyme-bound heme (Table S2). Hemin also was capable of catalyzing this
reaction when reduced with dithionite (Table S3, Figure 1). That hemin could catalyze this
reaction is consistent with earlier work investigating the activity of metal porphyrins in the
reaction with sulfonyl azides.[14] However, whereas in vitro enzyme reactions with prochiral
substrate 1 resulted in asymmetric induction (up to 73% ee, Table 1), reaction with hemin
unsurprisingly yielded only racemic 3, strongly suggesting that BM3-catalyzed amination
occurs within the chiral environment of the enzyme active site. Addition of sub-
stoichiometric amounts of NADPH was sufficient for activity (Table S4), supporting the
hypothesis that ferrous-heme is the azide-reactive state, akin to P450-catalyzed
cyclopropanation.[11] Dithionite could be used in place of NADPH to drive catalysis, where
its effect was comparable to that of NADPH for both cysteine- and serine-ligated enzymes
P450BM3-T268A and P411BM3-T268A (Table S5), indicating that reduction to ferrous heme
was not limiting.
To examine the effect of C-H bond strength on amination activity, P411BM3-CIS and
P411BM3-T268A were reacted with the trimethyl and triisopropyl analogs of 1 (substrates 4
and 6, respectively). The desired benzosultam products were obtained, though the
productivity was lower with both substrates (Figure 1, Table S3). Free hemin activity was
inversely correlated with the substrate C-H bond strength, consistent with earlier work on
cobalt porphyrin catalysts,[14] showing no measurable activity on substrate 4, minimal
activity on substrate 1 (3 TTN), and the highest activity on substrate 6 (55 TTN). The
differing patterns of activity observed with hemin and enzyme-catalyzed reactions suggest
that the enzyme itself plays a critical role in catalyzing C-N bond formation beyond
providing a chiral active site that guides the stereochemical outcome of the reaction. In
particular, enzyme reactions with triethyl and trimethyl sulfonylazide substrates 1 and 4
were markedly more productive than the corresponding hemin reactions. The reduced
activity of the enzyme toward triisopropyl substrate 6 suggests that the active site structure
currently favors smaller substrates, though it is likely that this can be modulated by further
enzyme engineering.
To determine whether this new reactivity could be exploited in vivo, we next investigated
whether these enzymes expressed in intact E. coli cells could catalyze amination reactions
when provided with azide substrate. Remarkably, both the P411BM3-T268A and P411BM3-
CIS enzymes were highly active on 1, catalyzing hundreds of turnovers (245 TTN, 89% ee
P411BM3-T268A, 680 TTN, 60% ee P411BM3-CIS) under anaerobic conditions with added
glucose (Tables 2, S6). Lyophilized cells containing P411BM3-CIS could also support
catalysis, with productivity similar to freshly-prepared cell suspensions (750 TTN, 61% ee).
Enantioselectivity was comparable or enhanced for whole-cell catalysts relative to purified
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enzymes (Table 2). Including the previously characterized T438S mutation in P411BM3-CIS
strongly increased enantioselectivity (430 TTN, 86% ee).[11, 15] Optimization of expression
conditions increased the productivity of whole-cell C-H amination catalysts, enabling
conversions to 3 of up to 66% in small-scale reactions (Table S7). Inspired by the simplicity
of employing whole cells as amination catalysts, we performed a preparative scale reaction
(50 mg) using anaerobic resting cells expressing the P411BM3-CIS-T438S catalyst, affording
sultam 3 (77% yield by HPLC, 69% isolated yield, 87% ee). The level of stereoselectivity
attained with whole-cell catalysts compared favorably with a previously reported chiral C-H
amination catalyst, which gave 88% ee in reaction with substrate 1.[16]
The beneficial effects of the T268A and C400S mutations for C-H amination is striking in
that both residues play critical roles in P450-catalyzed monooxygenation.[17] While
important for protonation of iron-peroxo intermediates that occur during dioxygen
activation, T268 may sterically hinder binding of bulkier azide substrates in C-H amination.
Consistent with a steric role, the T268A mutation enhances the stereoselectivity of C-H
amination; it also strongly impacts diastereo and enantioselectivity of styrene
cyclopropanation.[11] While thiolate ligation is thought to be essential for O-O bond scission
and enhancing the basicity of reactive oxygen intermediates,[13, 18] here we find that
mutation of this key residue leads to high levels of in vitro amination activity (Table 1). That
mutations to both T268 and C400 appear necessary for enzymatic C-H amination suggests
that naturally occurring P450s, in which these two residues are highly conserved, will likely
be poor catalysts of C-H amination.
Many enzyme-catalyzed reactions such as ketoreduction, monooxygenation, and
transamination are increasingly useful in chemical synthesis,[19] and applications of these
and other naturally-occurring reaction types will continue to develop. However, it is no
longer necessary to limit biocatalysis to reactions that have natural antecedents.[11, 20]
Rather, the scope of biocatalysis can be expanded by directing natural enzymes to imitate
the artificial, accessing whole new chemistries by judicial choice of reaction conditions,
synthetic reagents, and protein engineering.
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Figure 1.
Substrate selectivity of P411 enzymes compared with free hemin. Compounds used to test
the dependence of amination activity on C-H bond strength in reactions catalyzed by
enzyme (0.1 mol%) or hemin (1 mol%) are shown. Reaction conditions described in
supporting information.
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Scheme 1.
Initial reaction screening substrate and products
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Table 1
Comparison of activities (TTN) and enantioselectivies of purified P450 and P411 variants with azide 1 at 0.1
mol% catalyst loading giving sulfonamide 2 and benzosultam 3. Reaction conditions described in supporting
information. TTNs and enantioselectivies determined by HPLC analysis.
In vitro catalyst TTN[a] % ee[b]
P450BM3 2.1 nd
P450BM3-T268A 15 36
P411BM3 32 20
P411BM3-T268A 120 58
P411BM3-CIS 310 67
P411BM3-CIS-A268T 82 47
P411BM3-CIS-T438S 383 73
[a]
TTN = total turnover number
[b](S−R)/(S+R).
nd = not determined.
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Table 2
Comparison of C-H amination activities (TTN) of intact E. coli cells expressing P450 and P411 variants.
Reaction conditions described in supporting information.
In vivo catalyst [P450] or
[P411] µM % yield
[a]
(3)
TTN[b] % ee[c]
pCWori-empty 0 0 0 nd
P450BM3 6.6 0.5 5.1 nd
P450BM3-T268A 5.8 7.8 26 84
P411BM3 4.3 6.7 29 16
P411BM3-T268A 2.2 30 250 89
P411BM3-CIS 1.4 46 680 60
P411BM3-CIS-T438S 2.7 58 430 87
[a]
TTN = total turnover number
[b]
*(S−R)/(S+R).
nd = not determined.
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